In HDGC therapy, we use the term “synthetic lethality” to refer to pharmacological inhibition that preferentially inhibits the growth or survival of cancer cells that lack E-cadherin expression relative to wild-type cells [11]. The gene discussed is CDH1; the disease is cancer.